Trial Profile

An Open-label Single-dose Study to Evaluate the Pharmacokinetics of Sotorasib in Healthy Subjects and Subjects With Moderate or Severe Hepatic Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotorasib (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Amgen

Most Recent Events

24 Mar 2023 Results assessing need for dosing adjustments in subjects with moderate hepatic impairment (HI, Child-Pugh B) and severe HI (Child-Pugh C) presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
01 Apr 2022 Status changed from recruiting to completed.
16 Mar 2022 Planned End Date changed from 15 Feb 2022 to 8 Apr 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com